PD-L1，免疫调控大师 2.0。
PD-L1, a Master Regulator of Immunity 2.0.
机构信息
Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra-UPNA-IdISNA, 31008 Pamplona, Spain.
出版信息
Int J Mol Sci. 2023 Feb 23;24(5):4385. doi: 10.3390/ijms24054385.
Abstract
Since the introduction of the first anticancer treatments at the beginning of the 20th century, many different chemotherapeutics have been developed [...].
摘要
自 20 世纪初首次引入抗癌治疗以来，已经开发出许多不同的化疗药物[...]。
相似文献
1
PD-L1, a Master Regulator of Immunity 2.0.PD-L1，免疫调控大师 2.0。
Int J Mol Sci. 2023 Feb 23;24(5):4385. doi: 10.3390/ijms24054385.
2
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.树突状细胞决定对 PD-L1 阻断癌症免疫治疗的反应。
Sci Transl Med. 2020 Mar 11;12(534). doi: 10.1126/scitranslmed.aav7431.
3
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.5-氟尿嘧啶上调胃肠道癌中细胞表面 B7-H1（PD-L1）的表达。
J Immunother Cancer. 2016 Oct 18;4:65. doi: 10.1186/s40425-016-0163-8. eCollection 2016.
4
Regulation of PD-L1 Expression by NF-κB in Cancer.NF-κB 对肿瘤中 PD-L1 表达的调控。
Front Immunol. 2020 Nov 25;11:584626. doi: 10.3389/fimmu.2020.584626. eCollection 2020.
5
Serum Soluble PD-L1, PD-L2, and B7-H5 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer.血清可溶性 PD-L1、PD-L2 和 B7-H5 作为人类胰腺癌潜在的诊断生物标志物。
Clin Lab. 2021 Jun 1;67(6). doi: 10.7754/Clin.Lab.2021.210103.
6
Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.对胰腺腺癌组织石蜡包埋切片进行B7-H1（程序性死亡受体配体1）免疫组化染色。
J Vis Exp. 2013 Jan 3(71):4059. doi: 10.3791/4059.
7
Expression status of PD-L1 and B7-H3 in mesothelioma.间皮瘤中程序性死亡受体配体1（PD-L1）和B7-H3的表达状态
Pathol Int. 2020 Dec;70(12):999-1008. doi: 10.1111/pin.13028. Epub 2020 Oct 7.
8
Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.在低PD-L1表达的胶质瘤中，B7-H4表达增强可识别出超冷肿瘤。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2019-000154.
9
Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis.程序性死亡配体 1 作为肿瘤进展和转移的调节剂。
Int J Mol Sci. 2021 May 20;22(10):5383. doi: 10.3390/ijms22105383.
10
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.B7-H1（程序性死亡配体1，CD274）在T细胞淋巴增殖性疾病中抑制宿主免疫。
Blood. 2009 Sep 3;114(10):2149-58. doi: 10.1182/blood-2009-04-216671. Epub 2009 Jul 13.
本文引用的文献
1
Molecular targeted therapy for anticancer treatment.用于抗癌治疗的分子靶向治疗。
Exp Mol Med. 2022 Oct;54(10):1670-1694. doi: 10.1038/s12276-022-00864-3. Epub 2022 Oct 12.
2
Clinical landscape of LAG-3-targeted therapy.LAG-3靶向治疗的临床概况。
Immunooncol Technol. 2022 Mar 17;14:100079. doi: 10.1016/j.iotech.2022.100079. eCollection 2022 Jun.
3
Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?PD-L1状态的肿瘤间异质性：在临床决策中重要吗？
J Thorac Dis. 2020 May;12(5):1770-1775. doi: 10.21037/jtd-20-1661.
4
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.系统性血液免疫细胞群体作为免疫检查点抑制剂治疗结果的生物标志物。
Int J Mol Sci. 2020 Mar 31;21(7):2411. doi: 10.3390/ijms21072411.
5
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.PD-L1 在系统性免疫细胞群体中的表达作为预测肺癌对 PD-L1/PD-1 阻断治疗反应的潜在生物标志物。
Int J Mol Sci. 2019 Apr 2;20(7):1631. doi: 10.3390/ijms20071631.
6
The intracellular signalosome of PD-L1 in cancer cells.肿瘤细胞中 PD-L1 的细胞内信号复合物。
Signal Transduct Target Ther. 2018 Sep 28;3:26. doi: 10.1038/s41392-018-0022-9. eCollection 2018.
7
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.可溶性程序性死亡受体-1和程序性死亡配体-1：在癌症中的预测和预后意义
Oncotarget. 2017 May 31;8(57):97671-97682. doi: 10.18632/oncotarget.18311. eCollection 2017 Nov 14.
8
PD1 signal transduction pathways in T cells.T细胞中的PD1信号转导通路。
Oncotarget. 2017 Apr 19;8(31):51936-51945. doi: 10.18632/oncotarget.17232. eCollection 2017 Aug 1.
9
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.PDL1 通过保守序列基序发出信号，以克服干扰素介导的细胞毒性。
Cell Rep. 2017 Aug 22;20(8):1818-1829. doi: 10.1016/j.celrep.2017.07.075.
10
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?PD-L1 生物标志物检测在非小细胞肺癌中的应用：是真是假？
J Immunother Cancer. 2016 Aug 16;4:48. doi: 10.1186/s40425-016-0153-x. eCollection 2016.
Zotero 插件